MOLECULAR PARTNERS AG Weighted Average Exercise Price Of Other Equity Instruments Outstanding In Share-based Payment Arrangement2019
MOLECULAR PARTNERS AG (MOLN) had Weighted Average Exercise Price Of Other Equity Instruments Outstanding In Share-based Payment Arrangement2019 of 0.1 CHF/shares as of 2025-12-31, per its 20-F filed 2026-03-12.
Financial Statements › Notes › Compensation Related Costs
ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019 · last filed 2026-03-12
- 2025-12-31: Weighted Average Exercise Price Of Other Equity Instruments Outstanding In Share-based Payment Arrangement2019 0.10 CHF/shares.
- 2024-12-31: Weighted Average Exercise Price Of Other Equity Instruments Outstanding In Share-based Payment Arrangement2019 0.10 CHF/shares.
- 2024-06-30: Weighted Average Exercise Price Of Other Equity Instruments Outstanding In Share-based Payment Arrangement2019 0.10 CHF/shares.
- 2023-12-31: Weighted Average Exercise Price Of Other Equity Instruments Outstanding In Share-based Payment Arrangement2019 0.10 CHF/shares.
| Period end | Weighted Average Exercise Price Of Other Equity Instruments Outstanding In Share-based Payment Arrangement2019 |
|---|---|
| 2025-12-31 | 0.10 CHF/shares 20-F · filed 2026-03-12 |
| 2024-12-31 | 0.10 CHF/shares 20-F · filed 2026-03-12 |
| 2024-06-30 | 0.10 CHF/shares 6-K · filed 2024-08-26 |
| 2023-12-31 | 0.10 CHF/shares 20-F · filed 2026-03-12 |
| 2023-06-30 | 0.10 CHF/shares 6-K · filed 2023-08-24 |
| 2022-12-31 | 0.10 CHF/shares 20-F · filed 2025-03-06 |
| 2022-06-30 | 0.10 CHF/shares 6-K/A · filed 2022-08-31 |
| 2021-12-31 | 0.10 CHF/shares 20-F · filed 2024-03-14 |
| 2020-12-31 | 0.10 CHF/shares 20-F · filed 2023-03-09 |
| 2019-12-31 | 0.10 CHF/shares 20-F · filed 2022-03-15 |